EGFR inhibitor-mediated apoptosis in solid tumors

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 4, 2007, Pages 305-320

  Goel, Sanjay ^a   Hidalgo, Manuel ^b   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Apoptotic pathways; EGFR inhibition; EGFR inhibitor therapy; EGFR targeted therapy; Tumor survival

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LAPATINIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VECTIBIX;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 36148960809     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Aaronson SA. Growth factors and cancer. Science 254:1146-1153, 1991.
2. Baselga J, Arteaga CL. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. J Clin Oncol 23:2445-2459, 2005.
3. Wells A. EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999.
4. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37-46, 2004.
5. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9, 2001.
6. Yarden Y. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4:S3-S8, 2001.
7. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990.
8. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31, 2001.
9. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787, 2002.
10. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763-773, 2002.
11. Carpenter G. Employment of the epidermal growth factor receptor in growth factor- independent signaling pathways. J Cell Biol 146:697-702, 1999.
12. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology 2005.
13. Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 298:873-878, 2001.
14. Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor - mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 110:868-874, 2000.
15. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593-1611, 2002.
16. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
17. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48:137-141, 1988.
18. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133-1137, 1993.
19. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998.
20. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326, 1992.
21. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3-17, 1992.
22. Bucci B, D'Agnano I, Botti C, Mottolese M, Carico E, Zupi G, Vecchione A. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res 17:769-774, 1997.
23. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 74:214-220, 1994.
24. Glynne-Jones E, Goddard L, Harper ME. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27:688-694, 1996.
25. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998.
26. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4:S9-15, 2001.
27. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995.
28. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-4884, 2000.
29. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8:1253-1264, 2002.
30. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000.
31. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 21:8723-8731, 2002.
32. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10:794-801, 2004.
33. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966-971, 2004.
34. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493-2506, 1999.
35. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254, 2003.
36. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62:4307-4315, 2002.
37. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-31189, 2005.
38. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30:1-17, 2004.
39. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13:506-513, 2001.
40. Foltz I, King C, Liang M, Schooley K, Cerretti D, Freeman D, Radinsky R, Yang X-D. Panitumumab Induces Internalization of the Epidermal Growth Factor Receptor (EGFr). Presented at: AAACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract B43. 2005.
41. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157-161, 2005.
42. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001.
43. Sorkina T, Huang F, Beguinot L, Sorkin A. Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. J Biol Chem 277:27433-27441, 2002.
44. ImClone Systems. Cetuximab Prescribing Information, March 2006. 2006.
45. Amgen Inc. Vectibix™ [Package insert]. Thousand Oaks, CA: Amgen Inc.; 2006.
46. Bush T, Freeman D, Ogbagabriel S, Belmontes B, Kozlosky C, Baher A, Johnson C, Van G, Cerretti D, Radinsky R. Activity of panitumumab alone and in combination with chemotherapy against mutant epidermal growth factor receptor (EGFr)-expressing non-small lung carcinoma (NSCLC) cell lines and xenografts. Presented at: AAACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract B64. 2005.
47. Bush T, Freeman D, Ogbagabriel S, Ziegler B, Belmontes B, Van G, Johnson C, Radinsky R. Antitumor efficacy of panitumumab alone or in combination with chemotherapy against human pancreatic carcinoma xenografts. Presented at: AAACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract B72.
48. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23, 2001.
49. Blumenschein G, Jr., Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 24:7119-2006.
50. Crawford J, Burris III HA, Stein M, Stephenson J, Gilbert J, Underwood S, Sun Y, Yang L, Wiezorek J, Schwartzberg LS. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies. J Clin Oncol (Meeting Abstracts) 24:13005-2006.
51. Iressa® [package insert]. London, UK; AstraZeneca. 2004.
52. Tarceva™ [package insert]. Melville, NY; OSI Pharmaceuticals. 2004.
53. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 3. 2005.
54. Gatzemeier U, Heller A, Foernzler D, Moecks J, Ward C, De Rosa F. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib. Presented at: 2005 ASCO Annual Meeting; May 13-17, 2005; Orlando, FL. Abstract 7028.
55. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004.
56. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004.
57. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005.
58. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, Benson A, Wade J, Schilsky R, Mayer R. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24:3509-2006.
59. Borner M, Mingrone W, Koeberle D, Von Moos R, Rauch D, Saletti P, Herrmann R, Dietrich D, Lanz D, Roth A. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol (Meeting Abstracts) 24:3551-2006.
60. Colucci G, Giuliani F, Mattioli R, Garufi C, Mallamaci R, Pezzella G, Lopez M, Maiello E. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J Clin Oncol (Meeting Abstracts) 24:3559-2006.
61. Lang I, Zaluski J, Changchien CR, Makhson A, Pinter T, D'Haens G, Lim R, Nippgen J, Van Cutsem E. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL). J Clin Oncol (Meeting Abstracts) 24:3555-2006.
62. Abubakr Y, Eng C, Pautret V, Maurel J, Scheithauer W, Kroening H, Zubel A, Lutz M, Wong L, Sobrero A. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol 24:3556-2006.
63. Smith DM, Legoux J, Brunet R, Adhoute X, Blanc J, Fonck M, Vendrely V, Becouarn Y. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis. J Clin Oncol (Meeting Abstracts) 24:3558-2006.
64. Machiels JP, Sempoux C, Scalliet P, Coche JC, Coster B, Canon JL, Kerger J, Van Cutsem E, Peeters M, Haustermans K. Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. J Clin Oncol (Meeting Abstracts) 24:3552-2006.
65. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006.
66. Vermorken J.B., Mesia R, Villegas-Vega ME, Remenar E, Hitt R, Kawecki A, Rottey S, Zabolotnyy D, Erfan J, Amellal N. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). J Clin Oncol (Meeting Abstracts) 24:5537-2006.
67. Krempien RC, Munter MW, Timke C, Huber PE, Friess H, Heeger S, Herfarth KK, Abdollahi A, Hartung G, Buchler MW, Debus J. Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283]. J Clin Oncol (Meeting Abstracts) 24:4100-2006.
68. Pipas JM, Zaki B, Suriawinata AA, Tsapakos MJ, Ripple GH, Colacchio TA, Sutton JE, Gordon SR, Kasibhatla MS, Barth RJ, Jr. Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. J Clin Oncol (Meeting Abstracts) 24:14056-2006.
69. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial. J Clin Oncol 22:2610-2616, 2004.
70. Berlin J, Neubauer M, Swanson P, Harker WG, Burris H, Hecht JR, Navale L. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing >= 10% epidermal growth factor receptor (EGFr). J Clin Oncol (Meeting Abstracts) 24:3548-2006.
71. Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D'Avirro P, Amado R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol (Meeting Abstracts) 24:3547-2006.
72. Trarbach T, Schleucher N, Weber D, Tillner J, Fassmann I, Seeber S, Vanhoefer U. Phase I study of the humanized antiepidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma. Presented at: 2005 ASCO Annual Meeting; May 13-17, 2005; Orlando, FL. Abstract 3156.
73. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmieget W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94:1293-1299, 2006.
74. Strumberg D, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). J Clin Oncol (Meeting Abstracts) 24:12504-2006.
75. Brade AM, Siu L, Oza AM, Southwood B, De Borja M, Pond GR, Sherman IA, Chen E. A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 24:13054-2006.
76. Bode U, Buchen S, Janssen G, Reinhard T, Warmuth-Metz M, Bach F, Fleischhack G. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol (Meeting Abstracts) 24:1522-2006.
77. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-V, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003.
78. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van KM, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
79. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11:3369-3376, 2005.
80. Natale RB, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A, Germonpre P, Stockman P, Kennedy S, Ranson M. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol (Meeting Abstracts) 24:7000-2006.
81. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12:4441s-4445s, 2006.
82. Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W, Schlumberger M. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol (Meeting Abstracts) 24:5533-2006.
83. Hoffmann S, Glaser S, Wunderlich A, Lingelbach S, Dietrich C, Burchert A, Muller H, Rothmund M, Zielke A. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 2006.
84. Ravaud A, Gardner J, Hawkins R, Von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels J, El-Hariry I, Tykerb Renal Cell Cancer Study Group and GSK CoreT. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 24:4502-2006.
85. Harrington KJ, Bourhis J, Nutting CM, Rosine D, Theodosiou AM, Gardiner S, Berger MS, Beelen AP, Stead AG, El-Hariry IA. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 24:5553-2006.
86. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-8607, 2003.
87. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999.
88. Magne N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renee N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5- fluorouracil. Br J Cancer 89:585-592, 2003.
89. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 90:236-244, 2004.
90. Gilmore AP, Vaientijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277:27643-27650, 2002.
91. Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B, Ewert DL. Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Pmc Natl Acad Sci USA 94:5067-5072,1997.
92. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110 (Pt 2):113-121, 1997.
93. Jost M, Huggett TM, Kari C, Boise LH, Rodeck U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem 276:6320-6326, 2001.
94. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S, Gianni L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198:259-268, 2004.
95. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305:1163-1167, 2004.
96. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64:7241-7244, 2004.
97. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
98. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart SJ, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65:226-235, 2005.
99. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Janne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194, 2005.
100. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119-127, 1999.
101. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ. The function of multiple IkappaB:NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21:6510-6519, 2002.
102. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the antiepidermal growth factor antibody IMC-C225. J Gastrointest Surg 7:37-43, 2003.
103. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105:735-746, 2003.
104. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4:650-658, 2005.
105. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epdiermal growth factor receptor (GFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Presented at: ASCO Annual Meeting; May 31-June 4, 2003; Chicago, IL. Abstract 1012.
106. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Presented at: ASCO Annual Meeting; May 31-June 4, 2003; Chicago, IL. Abstract 817.
107. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163:303-312, 2003.
108. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105-5117, 2003.
109. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98:463-469, 2002.
110. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258, 2002.
111. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, Peters GE, Carroll WR, Waksal HW. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18:47S-53S, 2000.
112. Al-Hazzaa A, Bowen ID, Randerson P, Birchall MA. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells. Cell Prolif 38:77-86, 2005.
113. Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 92:125-130, 2005.
114. Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 15:809-818, 2004.
115. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747, 2000.
116. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62:4300-4306, 2002.
117. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328-3335, 2005.
118. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459-1470, 2005.
119. Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7:4156-4163, 2001.
120. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 54:1180-1193, 2002.
121. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74-82, 2000.
122. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000.
123. Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell-growth. Clin Cancer Res 5:875-881, 1999.
124. Cusack JC, Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 10:852-862, 2003.
125. Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara PN, Jr., Dakhil SR, Albain KS, Kim ES, Gandara DR. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. J Clin Oncol (Meeting Abstracts) 24:7015-2006.
126. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, von Pawel J. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 7010.
127. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler AB, Mass R, Johnson DH. TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 7011.
128. Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, Hidalgo M. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522-6527, 2004.
129. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 92:1846-1849, 2005.
130. Allen CT, Donovan EA, Chen Z, Gius D, Morris JC, Vanwaes C. Clinical, signaling pathway, and cellular effects of epidermal growth factor receptor (EGFR) inhibition with gefitinib in combination with paclitaxel and radiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 24:15540-2006.
131. Minna JD, Peyton MJ, Gazdar AF. Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst 97:1168-1169, 2005.
132. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355-5362, 2004.
133. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di CS, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501, 2004.
134. Fischel JL, Formento P, Milano G. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer 92:1063-1068, 2005.
135. Baselga J, Schoffski P, Rojo F, Dumez H, Ramos FJ, Macarulla T, Cajal R, Kisker O, Van Oosterom A, Tabernero J. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 24:3006-2006.
136. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133, 1993.
137. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18:155-161, 2000.
138. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22:432-443, 2001.
139. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133-1140, 2002.
140. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr., Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005.
141. Mininberg ED, Herbst RS, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting; May 31-June 4, 2003; Chicago, IL. Abstract 2521.
142. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12:4421s-4425s, 2006.
143. Dickler M, Rugo H, Caravelli J, Brogi E, Sachs D, Panageas K, Flores S, Moasser M, Norton L, Hudis C. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). Presented at: ASCO Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 2001.
144. Hainsworth JD, Sosman JA, Spigel DR, Schwert RC, Carrell DL, Hubbard F, Greco FA. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Presented at: ASCO Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 4502.
145. Saltz LB, Lenz H, Kindler H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Chen H. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at: ASCO 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Holly wood, FL. Abstract 169b.
146. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005.
147. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254-266, 2005.
148. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9:1566-1572, 2003.
149. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10:5930-5939, 2004.
150. Zhang X, Chen ZG, Choe MS, Lin Y, Sun S Y, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11:6261-6269, 2005.
151. Gadgeel SM, Ali S, Philip P, Wozniak A, Sarkar F. Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol (Meeting Abstracts) 24:7170-2006.
152. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005.
153. Piperdi B, Ling YH, Kroof G, Perez-Soler R. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. Presented at: ASCO Annual Meeting; June 5-8, 2004; New Orleans, LA. Abstract 7028.